Seizure in cerebral venous and sinus thrombosis

*Jafar Mehvari Habibabadi, *Mohammad Saadatnia, and †Nasim Tabrizi

Epilepsia Open, 3(3):316–322, 2018
doi: 10.1002/epi4.12229

Although the first reports of cerebral venous and sinus thrombosis (CVST) were published in the 19th century,1–3 the best approach to manage these patients and prevent the probable sequels is still a matter of debate. In comparison to arterial stroke, focal and generalized seizures are more commonly seen in CVST and have been known as presenting symptoms of disease since the first reports.4–6 Acute symptomatic seizures (ASS) occur in about 35–50% of all patients, with a higher incidence (76%) in peripartum CVST.7–10 Moreover post-CVST epilepsy (PCE) remained a troublesome sequel that might affect quality of life and needs long-term treatment with antiepileptic drugs (AEDs).4

Many factors have been postulated to predict acute phase and late-onset seizures, and to influence the decision of clinicians to start and continue treatment with AEDs.11–16 However, there is still a great deal of disagreement about the treatment of CVST-induced seizures. Primary prophylactic antiepileptic treatment has been suggested by a few studies.17 Other reports have recommended initiation of treatment after one or two seizures in the acute phase in patients with specific findings on neurological examination and neuroimaging.18–22 Data regarding duration of treatment and the best type and dosage of AEDs in the acute phase are also controversial.13,23,24 The level of evidence is low, and no powerful well-designed randomized controlled trial has targeted these issues.25

In this review we aimed to collect the existing data about incidence, semiology, and characteristics of seizures in CVST. We also discussed the predictive factors of early and late-onset seizures, their treatment, and prognosis.
**Key Points**

- Seizures are common consequences of cerebral venous and sinus thrombosis
- Acute symptomatic seizures frequently associate with focal neurological deficits and supratentorial lesions
- Post-CVST epilepsy has a strong correlation with history of acute symptomatic seizures
- Despite the lack of solid evidence, prophylactic treatment after first acute symptomatic seizure is recommended under certain circumstances

**Methods**

**Data sources and search strategy**

We performed a comprehensive search of the published literature from 1966–2016 using PubMed, Embase, Web of science, and Cochrane databases. The keywords included the following MESH and free terms: (1) CVT, (2) CVST, (3) CST (4), Cortical vein thrombosis, (5) Cerebral venous sinus thrombosis, and (6) Dural sinus thrombosis. We combined each of 6 words with the terms: (1) seizure, (2) epilepsy, (3) antiepileptic drugs, and (4) treatment.

**Study selection**

All abstracts were reviewed and assessed for relevance. In addition, we manually reviewed the references of relevant studies. The selected abstracts underwent full-text review to determine if they met following inclusion criteria: (1) Researches in adult humans (>16 years); (2) English language; (3) report of 10 or more patients; (4) presentation of data regarding incidence, characteristics, predictors, treatment, or prognosis of seizure in CVST.

Publications in other languages were considered only if they had an English abstract with adequate information. The studies that did not meet the criteria were excluded. We also considered review articles if they could provide more additional data. Figure 1 explains the full data-gathering process.

**Discussion**

**Definition and incidence**

Different timing methods have been used to classify seizure occurrence during the course of CVST. The most accurate classification is referred to Ferro et al., who assorted seizures into 3 groups including presenting seizures (before diagnosis of CVST), early seizures (within 14 days of diagnosis of CVST), and late seizures (after 14 days of diagnosis of CVST). But most of the studies have used the terms “acute” for both presenting and early seizures and “remote” for late seizures. According to recent definitions and terminology of seizure and epilepsy, in this review we have used the term “acute symptomatic seizures” (ASS) to address seizures within first 14 days of diagnosis and “post-CVST epilepsy” (PCE) to mention later seizures.

The incidence rate of ASS has a widely varied range in different studies. ASS in CVST are reported in 6.9–76% of patients, with the higher incidence in severe CVST cases (60%) and peripartum CVST (76%). The risk of PCE is low compared with the high rate of ASS, and is reported in about 4–16% of patients in different studies that followed patients between 12 months to a mean of 77.8 months. Based on the results of the international study on cerebral vein and dural sinus thrombosis (ISCVT), 11% of the patients experienced PCE (36 patients by 6 months, 55 by 1 year, and 66 by 2 years). Although the follow-up periods are different and in some studies unreliable ways of data gathering have been used that makes it difficult to draw an exclusive conclusion, there is a consensus on occurrence of most of PCE cases within the first year.

**Seizure type and semiology**

None of the reviewed studies investigated the relation between semiologic features of seizures and location of parenchymal lesions or venous system thrombosis.

In some studies the only or the prominent type of seizures was focal with or without secondary generalization.

Epilepsia partialis continua (EPC) has also been reported as a clinical manifestation of seizures. Masuhr et al. in 2004 described Todd’s paresis following seizures caused by CVST and introduced it as an indicator of CVST in the relevant setting, particularly if paresis switches between both
sides. In his next study at 2006, Todd’s paresis has been reported in 54.7% of patients following ASS.

However, in other studies, generalized seizures are reported to have a higher frequency, particularly in severe cases of CVST who underwent thrombolysis.

It is difficult to determine which type of seizures is more common due to controversial existing data. The other problem that causes concern about the reliability of the reported incidence of generalized seizures is the possible lack of close supervision at the time of seizure occurrence, which may cause unwanted neglect of brief focal semiology at onset.

Predictors of ASS

To provide a better understanding of the predictors of seizures in CVST, we classified them based on demographic factors, associated symptoms and signs, anatomical location, imaging findings, laboratory data, and treatment options.

Demographic factors

Age has no predictive role in ASS. In a study by Ferro et al. on CVST in the elderly, no difference regarding type (focal or generalized) and incidence of seizures was observed between young or middle-aged patients (<65 years) and elderly patients (≥65 years), either in the acute phase or follow-up. In addition, gender has no predictive value in seizure occurrence.

Symptoms and signs

In a study by Mahale et al. on predictors of ASS in CVST, altered mental status, Glasgow coma scale (GCS) score <8, and paresis had a meaningful association with ASS, whereas headache, vomiting, aphasia, sensory symptoms, and papilledema did not. The association of motor deficit with ASS is also confirmed by other studies, but in contrast to the Mahale study, aphasia was a predictor of ASS, in ISCVT, and in the VENOPORT study ASS were associated with sensory deficits. Conversely, the risk of early seizures in patients presenting with isolated intracranial hypertension is low (<3%) and the comparison of patients with and without headache as a presenting symptom has shown that seizures are significantly more common in patients without headache (58% vs. 32%). It can be obviously concluded that involvement of brain parenchyma at or near the motor cortex leading to motor or sensory deficit predisposes patients to ASS. However, the isolated intracranial hypertension, at least before causing loss of consciousness, has no role in this regard.

Anatomic involvement and imaging

ASS are most commonly reported in patients with supratentorial lesions, particularly of the frontal and parietal lobes. Davoudi et al. stated that lesions limited to one lobe were significantly associated with ASS, whereas involvement of more than one lobe showed no association.

Although in a retrospective multicenter study by Terazzi et al. and another study by Davoudi et al., seizure occurrence had no correlation to location of venous thrombosis, most studies reported that thrombosis of straight sinus and superior sagittal sinus are significantly associated with ASS. In addition, there are multiple reports of significant association between ASS and cortical vein thrombosis.

In contrast, patients with seizures had significantly less involvement of transverse and superficial sinuses. Damak et al., in their 9-year cohort study, compared 62 patients with isolated lateral sinus thrombosis and 133 with involvement of other parts of the cerebral venous system. They reported that seizures were significantly less frequent in isolated lateral sinus thrombosis than in other patients with CVST (16% vs. 47%).

Considering neuroimaging, ASS are more frequent in patients with focal edema, or ischemic or hemorrhagic infarcts. In cortical vein thrombosis, close contact of cortical veins to the cerebral cortex can cause local alterations of the blood–brain barrier and trigger seizures. Considering occlusion of the superior sagittal sinus and cortical veins, which drain venous blood from motor and sensory cortices, could increase the risk of seizures due to motor cortex damage. If hemorrhage occurs, focal cortical irritation caused by blood metabolites could also predispose acute seizures.

Etiology

Although Kalita et al. have found no role for underlying cause in predisposition for seizures; there are reports of possible effect of etiology. In a study by Davoudi et al., thrombophilia and a history of miscarriage were more common in patients with ASS. Evidence about pregnancy is more controversial. In some studies, CVST during pregnancy or the puerperal period was associated with a high incidence of seizures, whereas others did not find the same results. Possible predisposing factors for occurrence of seizures in this group of patients are reported as young age and concurrence of preeclampsia and fasting.

Lab

The only laboratory data that has associated significantly with ASS was high d-dimer levels. No data regarding the effect of other biochemical parameters on occurrence of seizures exist.

Treatment

Heparin therapy and time to start anticoagulant had no effect on the occurrence of ASS in CVST. In addition, no statistically significant difference has been reported between the incidence of ASS in patients who received unfractionated or low molecular weight heparin.
Predictors of PCE

Etiology

The only underlying cause mentioned in the literature to associate with a higher risk of PCE is thrombophilia.40

Symptoms and signs

Similar to ASS, paresis is reported as a risk factor of PCE, but no association of focal neurological signs other than motor deficit has been found. In the study by Davoudi et al.,40 loss of consciousness at presentation was significantly associated with PCE but such a relation has not been confirmed by other studies. ASS have a close association with development of PCE in patients with CVST11,40,59,60 and should be considered as a strong predictor.

Anatomical involvement and imaging

Supratentorial lesions are associated with late recurrence of seizures.40,72 In the study by Davoudi et al.,40 sigmoid sinus thrombosis and lesions in the occipital, temporal, and parietal lobes had a significant association with PCE. Such a relation between the involved lobe and PCE has not been reported by others.72 Presence of hemorrhage on admission imaging is considered as a risk factor for PCE as well.11,48,59

Treatment

As it is indicated by Price et al.,25 there is no well-designed randomized controlled trial regarding primary or secondary prevention of seizures in CVST and also there is no solid evidence to prove the effectiveness of prophylactic use of AEDs for prevention of seizures. Thus the decision-making regarding time, type, dosage, and duration of antiepileptic treatment in patients with CVST is often individualized. In a study by Coutinho et al.,78 the authors investigated expert opinions about treatment of CVST by invitation of corresponding authors of related papers during a 5-year period. They reported large practice variations regarding the use of prophylactic AEDs. The results indicated that 8% of experts initiate prophylactic AED in all patients, 21% prescribe prophylactic therapy only in patients with focal cerebral lesions, and the others (71%) did not recommend prophylaxis (p < 0.001).

There is low quality evidence about the effectiveness of prophylactic use of AEDs after first seizure in patients with CVST. But those authors who advocate this approach recommend prophylactic treatment because of the high incidence of seizures in CVST and the possibility of recurrence of seizures and status epilepticus in acute phase that might lead to deterioration of metabolic state and cause rise of intracranial pressure or even early death.17 However, most researchers restrict the use of AEDs to patients with seizures under certain circumstances.31 Prophylactic treatment recommended by these authors is limited to patients with supratentorial lesions such as edema, infarction, or hemorrhage on neuroimaging. Some studies particularly focused on the presence of hemorrhage and cortical vein thrombosis on imaging and focal motor and sensory deficits on neurological examination as indicators of a necessity to start prophylactic treatment.11,13,16,17,19–22,35,60,79–82

Despite all controversies, based on current data, prophylactic treatment with AEDs has no place in patients without focal neurologic deficits or supratentorial lesions, and might be harmful in these cases, as mentioned in the European Stroke Organization/European Academy of Neurology (ESO/EAN)83 and American Heart association/American Stroke Association (AHA/ASA) guidelines.80 Again, despite the lack of sufficient data, AHA/ASA guidelines suggested that in patients with CVST and no supratentorial lesion or focal neurologic deficits who experience a seizure, early initiation of AEDs for a defined period is probably recommended to prevent further seizures, whereas ESO/EAN guidelines presented no recommendations for these patients. Initiation of antiepileptic therapy only in patients who experienced repetitive seizures during the acute phase has fewer advocates.44

There is no consensus regarding the most appropriate type and dosage of AEDs.13,23,24,84 It seems reasonable that similar to the treatment approach for seizures accompanying a comorbidity, the best option is to select an AED with fewer drug interactions. When indicated, injectable forms of levetiracetam, lacosamide, and probably sodium valproate should be considered to prevent further seizures in the acute phase. However, for long-term treatment, levetiracetam, lamotrigine, and gabapentin are more appropriate options.

Moreover, no consensus exists about the duration of treatment. Whereas PCE is more common in patients with ASS and commonly occurs within the first 6–12 months after the acute stage, treatment with AED for 1 year is recommended for patients with ASS and previously indicated risk factors.11,12,21,31,32 However, in patients without these risk factors who have received AED therapy, gradual taper of AEDs after the acute stage seems reasonable.31 The approximate duration of 3 months could be considered for these patients; however, if seizures recurred during or after drug tapering, continuation of antiepileptic treatment for another 1–2 years or more is recommended.44 It is noteworthy that treatment with AEDs in the acute phase has no role in the prevention of PCE; therefore according to ESO/EAN guidelines, no recommendations can be made for prevention of PCE at the current time.83

Effect of seizures on CVST prognosis

Information about the effect of seizures on CVST prognosis is conflicting. Some studies have reported higher functional disability16,50,51 and mortality16,76,85,86 in patients with seizures. In a study by Stolz et al.,43 patients with more than 2 seizures despite treatment with AEDs had a significantly higher in-hospital mortality rate. Similarly, in the
study by Masuhr et al., occurrence of fewer than 3 seizures caused no significant difference regarding mortality. In this study, mortality rate was 3 times higher in patients with status epilepticus. In most of the other studies seizure was not associated with a worse outcome. Neither seizure nor status epilepticus had an effect on in-hospital mortality or 6-month outcome.

Two other studies have reported positive prognostic effect of seizures in CVST. In a study by Korathanakshun et al., seizure predicted the lower incidence of dependency or death, and in a study by Stam et al. on outcome of thrombolytic therapy in severe cases of CVST, seizures occurred less frequently in the fatal cases than in surviving patients. However, because altered mental status was among the inclusion criteria of the study and it could occur as a part of postictal phase in patients with less severe disease, the authors suggested the possibility of wrong selection of patients that led to this result.

There is no doubt that acute seizure is a warning symptom that might lead the clinicians to a more rapid diagnosis of CVST. These seizures more commonly occur in patients with structural lesions and motor deficits, which both could accompany long-term functional disability independent of seizure occurrence. The recurrence of seizures might be a sign of a more severe and diffuse process that not only involved multiple parts of the venous and sinus system but also caused severe edema, infarct, hemorrhage, or increase in intracranial pressure. Current data indicated that except for death instances that occur directly after seizures, in other severe cases, seizures are more likely a concomitant phenomenon rather than the etiology of functional disability or mortality. However, the adverse effects of PCE on a patient’s independence and quality of life cannot be overlooked.

CONCLUSION

The current literature data on seizure in CVST is full of disagreements. The observational findings about the semiology and localization of seizure-onset zone are imperfect. Predictors of seizure occurrence that play a significant role in determining the need for treatment are controversial and in the most important part, treatment, which causes a remarkable effect on seizure control and prognosis, no competent randomized clinical trial exist. It seems that there is an urgent need for conducting of clinical studies with the target of seizure in CVST, particularly the management issue.

DISCLOSURE

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

REFERENCES

1. Ribes M. Des recherches faites sur la phlébite. Rev Méd Fr 1824;6:1–4.
2. Trevithick E. Cerebral sinus thrombosis. Br Med J 1897;2:1166.
3. Abercrombie J. Pathological and practical researches on diseases of the brain and spinal cord. Edinburgh: Waugh & Innes; 1828: 83–85.
4. Nagpal RD. Dural sinus and cerebral venous thrombosis. Neurosurg Rev 1983;6:155–160.
5. Villringer A, Einhaupl KM. Dural sinus and cerebral venous thrombosis. New Horiz 1997;5:332–341.
6. Stewart RH. Primary cerebral sinus thrombosis. Br Med J 1942;2:455.
7. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin 1992;10:87–111.
8. Cantu C, Barrinagarrimenteria F. Cerebral venous thrombosis associated with pregnancy and puerperium. Review of 67 cases. Stroke 1993;24:1880–1884.
9. Einhaupl KM, Villringer A, Haberl RL, et al. Clinical spectrum of sinus venous thrombosis. In Einhaupl K, Kempski O, Baethmann A (Eds) Cerebral sinus thrombosis. Experimental and clinical aspects. New York, NY: Plenum Press; 1990:149–155.
10. Ferro JM, Correia M, Pontes C, et al. Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport). Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis 2001;11:177–182.
11. Ferro JM, Correia M, Rosas MJ, et al. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis 2003;15:78–83.
12. Preter M, Tzourio C, Ameri A, et al. Long-term prognosis in cerebral venous thrombosis: a follow-up of 77 patients. Stroke 1996;27:243–246.
13. Masuhr F, Busch M, Amberger N, et al. Risk and predictors of early epileptic seizures in acute cerebral venous and sinus thrombosis. Eur J Neurol 2006;13:852–856.
14. Ruiz-Sandoval JL, Chiqute E, Bañuelos Becerra LJ, et al. Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: the RENAMEVASC study. J Stroke Cerebrovasc Dis 2012;21:395–400.
15. Coutinho JM, Gerritsma JJ, Zuurberm SM, et al. Isolated cortical vein thrombosis: systematic review of case reports and case series. Stroke 2014;45:1836–1838.
16. Ferro JM, Canhão P, Bousser MG, et al. Early seizures in cerebral vein and dural sinus thrombosis: risk factors and role of antiepileptics. Stroke 2008;39:1152–1158.
17. Einhaupl KM, Masuhr F. Cerebral venous and sinus thrombosis – an update. Eur J Neurol 1994;1:109–126.
18. Wang X, Sun X, Liu H. Clinical analysis and misdiagnosis of cerebral venous thrombosis. Exp Ther Med 2012;4:923–927.
19. Ferro JM, Canhão P. Cerebral venous sinus thrombosis: update on diagnosis and management. Curr Cardiol Rep 2014;16:523.
20. Ferro JM, Canhão P. Acute treatment of cerebral venous and dural sinus thrombosis. Curr Treat Options Neurol 2008;10:126–137.
21. Coutinho JM, Stam J. How to treat cerebral venous and sinus thrombosis. J Thromb Haemost 2010;8:877–883.
22. Masuhr F, Mehracvin S, Einhaupl K. Cerebral venous and sinus thrombosis. J Neurol 2004;251:11–23.
23. Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 2004;21:639–653.
24. Mahale R, Mehta A, John AA, et al. Acute seizures in cerebral venous sinus thrombosis: what predicts it? Epilepsy Res 2016;123:1–5.
25. Price M, Günther A, Kwan JS. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database Syst Rev 2016;(4):CD005501.
26. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475–482.
27. Benten C, Martins H, Peralta AR, et al. Post-stroke seizures are clinically underestimated. J Neurol 2017;264:1978–1985.
28. Breteau G, Mounier-Vehier F, Godfroy O, et al. Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol 2003;250:29–35.
29. Gunen HN, Cokal BG, Guler SK, et al. Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis. J Int Med Res 2016;44:1454–1461.
Seizure in Cerebral Venous Thrombosis

30. Stam J, Majoie CB, van Delden OM, et al. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. *Stroke* 2008;39:1487–1490.

31. Einhäupl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. *Eur J Neurol* 2010;17:1229–1235.

32. Ferro JM, Canhão P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke* 2004;35:664–670.

33. Terni E, Giannini N, Chiti A, et al. Cerebral venous sinus thrombosis: clinical and pathogenetic perspectives from Tuscany. *Blood Coagul Fibrinolysis* 2015;26:505–508.

34. Patil VC, Choraria K, Desai N, et al. Clinical profile and outcome of cerebral venous sinus thrombosis at tertiary care center. *J Neurosci Rural Prac* 2014;5:218–224.

35. Borhani Haghighi A, Ashjazadeh N, Safari A, et al. Cerebral venous sinus thrombosis in Iran: cumulative data, shortcomings and future directions. *Ir J Red Crescent Med J* 2012;14:805–810.

36. Uzar E, Ekici F, Acar A, et al. Cerebral venous sinus thrombosis: an analyses of 47 patients. *Eur Rev Med Pharmaco Sci* 2012;16:1499–1505.

37. Fischer C, Goldstein J, Edlow J. Cerebral venous sinus thrombosis in the emergency department: retrospective analysis of 17 cases and review of the literature. *J Emerg Med* 2010;38:140–147.

38. Saadatnia M, Mousavi SA, Haghhighi S, et al. Cerebral vein and sinus thrombosis in Isfahan-Iran: a changing profile. *Can J Neurol Sci* 2004;31:474–477.

39. Rim HT, Jun HS, Ahn JH, et al. Clinical aspects of cerebral venous thrombosis at tertiary care center. *J Neurosci Rural Prac* 2014;5:218–224.

40. Ford TD, Williams PL, Caughey MS, et al. Prognostic indicators in cerebral venous sinus thrombosis. *J Neurol Neurosurg Psychiatry* 2003;71:139–144.

41. Wang L, Zhang J, Li W, et al. Clinical characteristics of cerebral venous thrombosis in patients with systemic lupus erythematosus: a single-centre experience in China. *J Immunol Res* 2015;2015:540738.

42. Narayanan JT, Murthy JM. Nonconvulsive status epilepticus in a neurological intensive care unit: profile in a developing country. *Epilepsia* 2007;48:900–906.

43. Ferro JM, Vasconcelos J, Canhão P, et al. Remote seizures in acute cerebral vein and dural sinus thrombosis (CVT): incidence and associated conditions. *Cerebrovasc Dis* 2007;23:48.

44. Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. *Clin Neurol Neurosurg* 2005;107:371–378.

45. Terazzi E, Mintto D, Ruda R, et al. Cerebral venous thrombosis: a retrospective multicentre study of 48 patients. *Neurosci Lett* 2005;325:311–315.

46. Sinha S, Satischandra P, Epilepsia Partialis Continua over last 14 years: experience from a tertiary care center from south India. *Epilepsy Res* 2007;74:55–59.

47. Ferro JM, Canhão P, Bousser MG, et al. Cerebral vein and sinus thrombosis in elderly patients. *Stroke* 2005;36:1927–1932.

48. Coutinho JM, Ferro JM, Canhão P, et al. Cerebral venous sinus thrombosis in women. *Stroke* 2009;40:2356–2361.

49. Bousser MG, Russell RR. Cerebral venous thrombosis. In: Warlow CP, Van Gijn J (Eds) *Major problems in neurology*. London, UK: WB Saunders; 1997:27–29.

50. Coutinho JM, Stam J, Canhão P, et al. Cerebral venous sinus thrombosis in the absence of headache. *Stroke* 2015;46:245–247.

51. Rathakrishnan R, Sharma VK, Luen TH, et al. The clinico-radiological spectrum of isolated cortical vein thrombosis. *J Clin Neurosci* 2011;18:1408–1411.

52. Damak M, Crassard I, Wolff V, et al. Isolated lateral sinus thrombosis: a series of 62 patients. *Stroke* 2009;40:476–481.

53. Girot M, Ferro JM, Canhão P, et al. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. *Stroke* 2007;38:337–342.

54. Kucukkaya B, Aker R, Yuksel M, et al. Low dose MK-801 protects against iron-induced oxidative changes in a rat model of focal epilepsy. *Brain Res* 1998;788:133–136.

55. Willmore LJ. Post-traumatic seizures. *Neural Clin* 1993;11:823–834.

56. Kalita J, Chandra S, Misra UK. Significance of seizure in cerebral venous sinus thrombosis. *Seizure* 2012;21:639–642.

57. Srinivasan K. Cerebral venous and arterial thrombosis in pregnancy and puerperium: a study of 135 patients. *Angiology* 1983;34:731–746.

58. Mehraan S, Ortwein H, Busch M, et al. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. *J Neurol Neurosurg Psychiatry* 2003;74:814–816.

59. Lu YT, Hsu CW, Tsai WC, et al. Status epilepticus associated with pregnancy: a cohort study. *Epilepsia Behav* 2016;59:92–97.

60. Jalili M, Ghourchian S, Shahidi GA, et al. A study of factors associated with cerebral venous thrombosis. *Neurosci Lett* 2013;43:321–326.

61. Coutinho JM, Ferro JM, Canhão P, et al. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. *Stroke* 2010;41:2575–2580.

62. Coutinho JM, Seelig R, Bousser MG, et al. Treatment variations in cerebral venous thrombosis: an international survey. *Cerebrovasc Dis* 2011;32:298–300.

63. Ferro JM, Canhão P, Aguia de Sousa D. Cerebral venous thrombosis. *Presse Med* 2016;45:6429–6450.

64. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2011;42:1158–1192.
81. Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of co-prescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. *Epilepsia* 2010;51:797–804.
82. Messe SR, Sansing LH, Cucchiara BL, et al. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. *Neurocrit Care* 2009;11:38–44.
83. Ferro JM, Bousser MG, Canhão P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. *Eur J Neurol* 2017;24:1203–1213.
84. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med* 2005;165:1095–1106.
85. Beghi E, D’Alessandro R, Beretta S, et al. Incidence and predictors of acute symptomatic seizures after stroke. *Neurology* 2011;77:1785–1793.
86. Canhão P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. *Stroke* 2005;36:1720–1725.
87. Lee DJ, Ahmadpour A, Binyamin T, et al. Management and outcome of spontaneous cerebral venous sinus thrombosis in a 5-year consecutive single-institution cohort. *J Neurointerv Surg* 2017;9:34–38.
88. Ferro JM, Bacelar-Nicolau H, Rodrigues T, et al. Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis. *Cerebrovasc Dis* 2009;28:39–44.
89. Borhani Haghighi A, Edgell RC, Cruz-Flores S, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. *Stroke* 2012;43:262–264.
90. Ferro JM, Canhão P, Stam J, et al. Delay in the diagnosis of cerebral vein and dural sinus thrombosis: influence on outcome. *Stroke* 2009;40:3133–3138.